

JOHNSON & JOHNSON
SELECTED PHARMACEUTICALS IN LATE STAGE U.S. and E.U. DEVELOPMENT OR REGISTRATION
As of July 15, 2008*

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
Central Nervous System	INVEGA (paliperidone ER OROS)	Bipolar mania Schizoaffective disorder	Phase III Phase III	Phase III
	paliperidone palmitate IM long acting injectable	Schizophrenia (1)	Filed 10/07	Phase III
	RISPERDAL CONSTA (risperidone)	Bipolar maintenance - long acting injectable (2), Deltoid injection (2) (5)	Filed 4/08 Filed 11/07	Phase III
	carisbamate (RWJ333369)	Epilepsy (6)	Phase III	Phase III
	TOPAMAX (topiramate)	Pediatric exclusivity	Filed 4/08	
	CONCERTA (OROS methylphenidate)	Adult attention deficit hyperactivity disorder	Approved 6/08	Phase III
Gastrointestinal	REMICADE (infliximab)	Pediatric Ulcerative Colitis Ulcerative Colitis - colectomy avoidance	Phase III Filed 8/07	Approved 4/08 (3)
Immunology	CNTO 1275 (ustekinumab)	Psoriasis (SC)	Filed 11/07	Filed 12/07
	CNTO 148 (golimumab)	Rheumatoid Arthritis (SC) Ankylosing Spondylitis (SC) Psoriatic Arthritis (SC) Rheumatoid Arthritis (IV)	Filed 6/08 Filed 6/08 Filed 6/08 Phase III	Filed 2/08 (3) Filed 2/08 (3) Filed 2/08 (3) Phase III (3)
Hematology	PROCRIT	Chronic Renal Function - extended dosing	Phase III	
Infectious Disease	ceftobiprole	Complicated Skin and Skin Structure Infections (6) Nosocomial Pneumonia (6) Hospitalized community acquired pneumonia (CAP) (6)	FDA approvable letter 3/08 Phase III Phase III	Filed 6/07 Phase III Phase III
	DORIBAX (doripenem)	Complicated Urinary Tract Infections (6) Complicated Intra-abdominal Infections (6) Nosocomial Pneumonia (6)	Approved 10/07 Approved 10/07 Filed 6/07	Positive CHMP Opinion 6/08 Positive CHMP Opinion 6/08 Positive CHMP Opinion 6/08
Oncology	DOXIL (doxorubicin HCl liposome injection)	Breast Cancer	Phase III	
	VELCADE	Non-Hodgkin's Lymphoma (6) Multiple Myeloma 1st line (6) Mantle Cell Lymphoma 1st line (6)		Phase III Filed 12/07 Phase III
	YONDELIS (trabectedin)	Relapsed Ovarian Cancer (6)	Phase III	
	DACOGEN (decitabine) for Injection	Myelodysplastic Syndromes (MDS) (6) Acute Myeloid Leukemia (6)		Phase III Phase III
Anti-Viral	PREZISTA (TMC114)	Treatment -naïve patients Early experienced patients	Filed 12/07 Filed 12/07	Phase III Filed 2/08
	INTELENCE (TMC125)	NNRTI HIV/AIDS treatment-experienced patients	Approved 1/08	Positive CHMP Opinion 6/08
	telaprevir	Chronic hepatitis C virus (HCV) infection		Phase III (6)
	TMC278	NNRTI HIV/AIDS treatment-naïve patients	Phase III	Phase III
Pain Management	tapentadol (R331333)	Moderate to severe acute pain (IR formulation) (6) Moderate to severe chronic pain (ER formulation) (6)	Filed 1/08 Phase III	
Cardiovascular	rivaroxaban	VTE Prophylaxis (Prevention of venous thromboembolism in hip and knee replacement surgery) (6) Stroke prevention in atrial fibrillation (6) VTE treatment (6) Medically III (6)	Phase III Phase III Phase III Phase III	
Reproductive Health	dapoxetine	Premature ejaculation (6)	FDA non-approvable letter 10/05	Filed 12/07 (4)

* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

- (1) Collaboration with Elan Corporation, plc
- (2) Collaboration with Alkermes, Inc.
- (3) Schering-Plough has EU marketing rights
- (4) Select EU countries
- (5) PK Trial - comparative single-dose pharmacokinetics of deltoid and gluteal injection

(6) Carisbamate licensed from SK-Bio Pharmaceuticals, ceftobiprole from Basilea Pharmaceutica, doripenem from Shionogi & Co., Velcade from Millennium Pharmaceuticals, The Takeda Oncology Company, Yondelis from PharmaMar, Dacogen from Eisai Corporation of North America, tapentadol from Grunenthal GMBH, rivaroxaban from Bayer HealthCare, Dapoxetine from PPD-GenuPro, telaprevir licensed from Vertex Pharmaceuticals Incorporated